Search

Getting the Duke Elder examination right: reflections and tips from a medical student

The Duke Elder undergraduate prize examination is an annual exam organised by the Royal College of Ophthalmologists in the United Kingdom. Named after Sir Stewart Duke Elder, a prominent British ophthalmologist, the exam is designed to encourage undergraduate medical students...

My Top Five: Promising gene therapies for ocular conditions

Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in treating inherited retinal diseases. This article reviews the top five gene therapies in late-stage trials,...

Getting one’s eye in

Lisette Bijma, Sister in the Eye Emergency Department at John Radcliffe Hospital, explains how COVID-19 provided a ‘baptism by fire’ and enabled fundamental and positive changes to the running of the department. Five years ago, I arrived in the UK,...

IN FOCUS - VISION 2020 LINKS Programme: the contribution of health partnerships to reduction in blindness worldwide

As other articles in this series (IN FOCUS Apr 2020) demonstrate, the year 2020 is highly significant in the eye care field. Naming a global initiative ‘VISION 2020: The Right to Sight’ in 1999 was a daring way to focus...

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...

Effect of the COVID-19 Urgent Eyecare Service on patient referrals to general practitioners and Hospital Eye Service

The COVID-19 Urgent Eyecare Services (CUES) was developed to relieve the demands of hospital ophthalmology, aiming to allow patients to have remote consultations and be managed by community optometric practice. This was because access to Hospital Eye Service (HES) Ophthalmic...

Intravitreal injections delivered by ophthalmic clinical nurse specialists

Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...